December 26, 2013 | Israeli biomed company Oramed Pharmaceuticals, which is developing an insulin pill to replace injection-based treatments of diabetes, has raised $13 million in a private placement on Nasdaq. “Globes” reports that the funds were raised from Special Situation Fund and Sabby Capital Healthcare.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments